Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway

Megumi Tago, Tatsuaki Nagata, Kenji Tago, Masaki Tsukada, Kazuyuki Tanaka, Shigeo Nakamura, Tadahiko Mashino, Tadashi Kasahara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The constitutively activated mutation (V617F) of tyrosine kinase Janus kinase 2 (JAK2) is found in the majority of patients with myeloproliferative neoplasms (MPNs). The development of a novel chemical compound to suppress JAK2 V617F mutant-induced onset of MPNs and clarification of the signaling cascade downstream of JAK2 V617F mutant will provide clues to treat MPNs. Here we found that a water-soluble pyrrolidinium fullerene derivative, C60-bis (N, N-dimethylpyrrolidinium iodide), markedly induced apoptosis of JAK2 V617F mutant-induced transformed cells through a novel mechanism, inhibiting c-Jun N-terminal kinase (JNK) activation pathway but not generation of reactive oxygen species (ROS). Pyrrolidinium fullerene derivative significantly reduced the protein expression level of apoptosis signal-regulating kinase 1 (ASK1), one of the mitogen-activated protein kinase kinase kinases (MAPKKK), resulting in the inhibition of upstream molecules of JNK, mitogen-activated protein kinase kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7). Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant. Furthermore, administration of both SP600125 and pyrrolidinium fullerene derivative markedly inhibited JAK2 V617F mutant-induced tumorigenesis in nude mice. Taking these findings together, JAK2 V617F mutant-induced JNK signaling pathway is an attractive target for MPN therapy, and pyrrolidinium fullerene derivative is now considered a candidate potent drug for MPNs.

Original languageEnglish
Pages (from-to)2024-2034
Number of pages11
JournalCellular Signalling
Volume24
Issue number11
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Janus Kinase 2
Fullerenes
JNK Mitogen-Activated Protein Kinases
MAP Kinase Kinase Kinase 5
MAP Kinase Kinase Kinases
Neoplasms
Apoptosis
MAP Kinase Kinase Kinase 4
Iodides
Nude Mice
Protein-Tyrosine Kinases
Reactive Oxygen Species
Carcinogenesis
Mutation
Water
Therapeutics

Keywords

  • Apoptosis
  • Apoptosis signal-regulating kinase 1 (ASK1)
  • C-Jun N-terminal kinase (JNK)
  • Fullerene
  • JAK2 V617F mutation
  • Myeloproliferative neoplasms (MPNs)

ASJC Scopus subject areas

  • Cell Biology

Cite this

Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. / Tago, Megumi; Nagata, Tatsuaki; Tago, Kenji; Tsukada, Masaki; Tanaka, Kazuyuki; Nakamura, Shigeo; Mashino, Tadahiko; Kasahara, Tadashi.

In: Cellular Signalling, Vol. 24, No. 11, 11.2012, p. 2024-2034.

Research output: Contribution to journalArticle

Tago, Megumi ; Nagata, Tatsuaki ; Tago, Kenji ; Tsukada, Masaki ; Tanaka, Kazuyuki ; Nakamura, Shigeo ; Mashino, Tadahiko ; Kasahara, Tadashi. / Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. In: Cellular Signalling. 2012 ; Vol. 24, No. 11. pp. 2024-2034.
@article{74480fa695704ab29200b049db73ce29,
title = "Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway",
abstract = "The constitutively activated mutation (V617F) of tyrosine kinase Janus kinase 2 (JAK2) is found in the majority of patients with myeloproliferative neoplasms (MPNs). The development of a novel chemical compound to suppress JAK2 V617F mutant-induced onset of MPNs and clarification of the signaling cascade downstream of JAK2 V617F mutant will provide clues to treat MPNs. Here we found that a water-soluble pyrrolidinium fullerene derivative, C60-bis (N, N-dimethylpyrrolidinium iodide), markedly induced apoptosis of JAK2 V617F mutant-induced transformed cells through a novel mechanism, inhibiting c-Jun N-terminal kinase (JNK) activation pathway but not generation of reactive oxygen species (ROS). Pyrrolidinium fullerene derivative significantly reduced the protein expression level of apoptosis signal-regulating kinase 1 (ASK1), one of the mitogen-activated protein kinase kinase kinases (MAPKKK), resulting in the inhibition of upstream molecules of JNK, mitogen-activated protein kinase kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7). Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant. Furthermore, administration of both SP600125 and pyrrolidinium fullerene derivative markedly inhibited JAK2 V617F mutant-induced tumorigenesis in nude mice. Taking these findings together, JAK2 V617F mutant-induced JNK signaling pathway is an attractive target for MPN therapy, and pyrrolidinium fullerene derivative is now considered a candidate potent drug for MPNs.",
keywords = "Apoptosis, Apoptosis signal-regulating kinase 1 (ASK1), C-Jun N-terminal kinase (JNK), Fullerene, JAK2 V617F mutation, Myeloproliferative neoplasms (MPNs)",
author = "Megumi Tago and Tatsuaki Nagata and Kenji Tago and Masaki Tsukada and Kazuyuki Tanaka and Shigeo Nakamura and Tadahiko Mashino and Tadashi Kasahara",
year = "2012",
month = "11",
doi = "10.1016/j.cellsig.2012.06.014",
language = "English",
volume = "24",
pages = "2024--2034",
journal = "Cellular Signalling",
issn = "0898-6568",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway

AU - Tago, Megumi

AU - Nagata, Tatsuaki

AU - Tago, Kenji

AU - Tsukada, Masaki

AU - Tanaka, Kazuyuki

AU - Nakamura, Shigeo

AU - Mashino, Tadahiko

AU - Kasahara, Tadashi

PY - 2012/11

Y1 - 2012/11

N2 - The constitutively activated mutation (V617F) of tyrosine kinase Janus kinase 2 (JAK2) is found in the majority of patients with myeloproliferative neoplasms (MPNs). The development of a novel chemical compound to suppress JAK2 V617F mutant-induced onset of MPNs and clarification of the signaling cascade downstream of JAK2 V617F mutant will provide clues to treat MPNs. Here we found that a water-soluble pyrrolidinium fullerene derivative, C60-bis (N, N-dimethylpyrrolidinium iodide), markedly induced apoptosis of JAK2 V617F mutant-induced transformed cells through a novel mechanism, inhibiting c-Jun N-terminal kinase (JNK) activation pathway but not generation of reactive oxygen species (ROS). Pyrrolidinium fullerene derivative significantly reduced the protein expression level of apoptosis signal-regulating kinase 1 (ASK1), one of the mitogen-activated protein kinase kinase kinases (MAPKKK), resulting in the inhibition of upstream molecules of JNK, mitogen-activated protein kinase kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7). Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant. Furthermore, administration of both SP600125 and pyrrolidinium fullerene derivative markedly inhibited JAK2 V617F mutant-induced tumorigenesis in nude mice. Taking these findings together, JAK2 V617F mutant-induced JNK signaling pathway is an attractive target for MPN therapy, and pyrrolidinium fullerene derivative is now considered a candidate potent drug for MPNs.

AB - The constitutively activated mutation (V617F) of tyrosine kinase Janus kinase 2 (JAK2) is found in the majority of patients with myeloproliferative neoplasms (MPNs). The development of a novel chemical compound to suppress JAK2 V617F mutant-induced onset of MPNs and clarification of the signaling cascade downstream of JAK2 V617F mutant will provide clues to treat MPNs. Here we found that a water-soluble pyrrolidinium fullerene derivative, C60-bis (N, N-dimethylpyrrolidinium iodide), markedly induced apoptosis of JAK2 V617F mutant-induced transformed cells through a novel mechanism, inhibiting c-Jun N-terminal kinase (JNK) activation pathway but not generation of reactive oxygen species (ROS). Pyrrolidinium fullerene derivative significantly reduced the protein expression level of apoptosis signal-regulating kinase 1 (ASK1), one of the mitogen-activated protein kinase kinase kinases (MAPKKK), resulting in the inhibition of upstream molecules of JNK, mitogen-activated protein kinase kinase 4 (MKK4) and mitogen-activated protein kinase kinase 7 (MKK7). Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant. Furthermore, administration of both SP600125 and pyrrolidinium fullerene derivative markedly inhibited JAK2 V617F mutant-induced tumorigenesis in nude mice. Taking these findings together, JAK2 V617F mutant-induced JNK signaling pathway is an attractive target for MPN therapy, and pyrrolidinium fullerene derivative is now considered a candidate potent drug for MPNs.

KW - Apoptosis

KW - Apoptosis signal-regulating kinase 1 (ASK1)

KW - C-Jun N-terminal kinase (JNK)

KW - Fullerene

KW - JAK2 V617F mutation

KW - Myeloproliferative neoplasms (MPNs)

UR - http://www.scopus.com/inward/record.url?scp=84865334665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865334665&partnerID=8YFLogxK

U2 - 10.1016/j.cellsig.2012.06.014

DO - 10.1016/j.cellsig.2012.06.014

M3 - Article

C2 - 22750290

AN - SCOPUS:84865334665

VL - 24

SP - 2024

EP - 2034

JO - Cellular Signalling

JF - Cellular Signalling

SN - 0898-6568

IS - 11

ER -